XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2021
Stockholders' Equity Note [Abstract]  
Schedule of the changes in outstanding warrants
   Number of Shares   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Term
(Years)		   Aggregate Intrinsic
Value		 
Outstanding and expected to vest at December 31, 2019   3,615,602   $19.96    9.2   $74,837,043 
Granted   1,000,000    39.50    9.3    
-
 
Exercised   (253,927)   
-
    
-
    
-
 
Forfeited   (455,938)   
-
    
-
    
-
 
Outstanding and expected to vest at December 31, 2020   3,905,737   $24.32    8.4   $48,952,339 
Granted   7,057,004    21.15    9.8    
-
 
Exercised   (174,619)   
-
    
-
    
-
 
Forfeited   (457,500)   
-
    
-
    
-
 
Outstanding and expected to vest at December 31, 2021   10,330,622   $22.52    9.0   $46,088,534 
Options exercisable at December 31, 2021   2,140,490   $20.99    7.3   $19,511,463 

 
Schedule of weighted average fair value of options
   Years Ended   Years Ended 
   December 31,   December 31, 
   2021   2020 
Risk free interest rate  0.59 to 1.31%  0.36 to 0.83%
Dividend yield   0%   0%
Volatility     97-101 %     101-108%
Expected term (in years)     5 to 6.25      6.25 

  
Schedule of the changes in outstanding warrants
   Number of Shares   Weighted Average Exercise Price Per Share 
Outstanding at December 31, 2019   3,646,870   $6.83 
Issued   250,000   $33.32 
Exercised   (1,211,199)  $7.27 
Forfeited/Expired   (15,040)  $16.80 
Outstanding at December 31, 2020   2,670,633   $9.11 
Issued   972,000   $31.98 
Exercised   (433,856)  $6.06 
Outstanding at December 31, 2021   3,208,777   $16.45 
Warrants exercisable at December 31, 2021   2,767,246   $13.92 

 
Schedule of stock-based compensation expense
   Year Ended   Year Ended 
   December 31,   December 31, 
   2021   2020 
Research and development  $15,835,900   $4,038,500 
General and administrative   24,658,600    16,738,800 
Total  $40,494,500   $20,777,300